Short Talks Selected from Proffered Abstracts

PR-01 Highlighting the combined effects of BMI and polygenic risk score on endometrial cancer risk. Tracy A. O’Mara. QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.


PR-03 The Combination of the Glucagon Like Peptide-1 Receptor Agonist Semaglutide and the Progestin Levonorgestrel is Highly Effective in Preclinical Studies of Endometrial Cancer. Kimberly K. Leslie. The University of New Mexico, Albuquerque, New Mexico, United States.

PR-04 CD73 is a novel repressor of mutant β-catenin oncogenic activity in endometrial cancer. Rebecca M. Hirsch. UNC Chapel Hill, Chapel Hill, North Carolina, United States.


PR-06 ARID1A/B mutations retarget mSWI/SNF chromatin remodeler activity and define a spectrum of dedifferentiation in endometrial carcinoma. Jessica D. St. Laurent. Brigham and Women’s Hospital, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States.


Disparities

A001 **Tracking the Relationship between Accrual and Comorbidities in Clinical Trial Enrollment (TRACE)**. Kemi Doll. University of Washington, Seattle, Washington, United States.

A002A **In-silico screening of race-specific endometrial cancer methylation markers using machine learning techniques**. Huma Asif. Northwestern University, Chicago, Illinois, United States.


A004 **Performance of the laparoscopic hysterectomy readmission score among diverse women with endometrial cancer**. Ashley Felix. The Ohio State University, Columbus, Ohio, United States.


A006 **Interruption fasting in combination with PD-inhibitor treatment as an innovative treatment strategy in a pre-clinical model of obesity-driven endometrial cancer**. Jennifer Haag. University of North Carolina, Durham, North Carolina, United States.

A007 **Addressing obesity’s impact on the PTEN mutant endometrium**. Hilary Skalski. Michigan State University, Grand Rapids, Michigan, United States.

A008 **Mitochondrial depletion and metabolic reprogramming is a novel phenotype of Lynch syndrome-related endometrial carcinogenesis**. Mikayla Bowen. MD Anderson Cancer Center, Houston, Texas, United States.

Targeted Therapeutics

A009 **The Combination of the Glucagon Like Peptide-1 Receptor Agonist Semaglutide and the Progestin Levonorgestrel is Highly Effective in Preclinical Studies of Endometrial Cancer**. Kimberly Leslie. The University of New Mexico, Albuquerque, New Mexico, United States.

A010 **Genomic landscape of somatic alterations identified in endometrial cancer using liquid biopsy**.


NXP800, a novel, small molecule GCN2 kinase activator, demonstrates potent single-agent activity in ARID1A and ARID1B-deficient endometrial cancer xenograft models. Ramez Eskander. Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of California San Diego Rebecca and John Moores Cancer Center, La Jolla, California, United States.


A phase 2, open-label, single-arm, prospective, multicenter study of nab-sirolimus plus letrozole in advanced or recurrent endometrioid endometrial cancer. Lauren Dockery. Stephenson Cancer Center, Oklahoma University Health, Oklahoma City, Oklahoma, United States.


Highlighting the combined effects of BMI and polygenic risk score on endometrial cancer risk. Tracy O'Mara. QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.

Pilot study of daily exemestane in patients with Endometrial Intraepithelial Neoplasia (EIN) or grade 1 endometrial cancer. Britt Erickson. University of Minnesota, Minneapolis, Minnesota, United States.

Detecting Cardiovascular Disease Risk in Early-Stage Endometrial Cancer Survivors: Preliminary Evidence of Pulse Wave Velocity and Social Vulnerability Index. Lauren Bates-Fraser. University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States.

Molecular Mechanisms

B001 **CD73 is a novel repressor of mutant β-catenin oncogenic activity in endometrial cancer.** Rebecca M. Hirsch. UNC Chapel Hill, Chapel Hill, North Carolina, United States.

B002 **ARID1A Loss Activates MAPK Signaling via DUSP4 Downregulation: A Mechanistic Insight in Endometrial Carcinoma.** Jayaprakash Mandal. Johns hopkins University School of Medicine, Baltimore, Maryland, United States.

B003 **Patient derived organoide as a model to study estrogen mediated endometrial cancer.** Breanna BW. Jeffcoat. University of North Carolina Chapel Hill, Chapel Hill, North Carolina, United States.

B004 **Investigating loss of ARID1A protein on endometrial cancer progression through the destabilization of adherens junctions.** Savannah E. Wright. University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States.

B005 **Proteomic profiling of endometrial carcinomas.** Dawn Cochrane. BC Cancer, Vancouver, British Columbia, Canada.

B006 **Mutant PPP2R1A Induces the Expression and Secretion of IGFBP2 to Promote Uterine Serous Carcinoma Metastasis.** Terrance James Haanen. University of Michigan, Ann Arbor, Ann Arbor, Michigan, United States.

B007 **Investigation of the mechanism of PADI2 regulation by the FBXW7 tumor suppressor.** Chandra Mani Kafle. National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, United States.

B008 **Modeling radiation sensitivity in patient-derived organoid models of endometrial cancer.** Sofia Gabrilovich. University of Iowa, Iowa City, Iowa, United States.

Targeted Therapeutics

B009 **Global Expression Analysis of Endometrial Cancer Cells in Response to Progesterone Identifies New Therapeutic Targets.** Kristina Thiel. University of Iowa, Iowa City, Iowa, United States.

B010 **Response to treatment with nab-sirolimus among patients with primary uterine tumors: A subgroup analysis from AMPECT.** Norma A. Palma. Aadi Bioscience, Pacific Palisades, California, United States.

B011 **Phase 2, multicenter, open-label basket trial of nab-sirolimus for malignant solid tumors harboring pathogenic inactivating alterations in TSC1 and TSC2 (PRECISION I).** Debra L. Richardson. Stephenson Cancer Center, OU Health, Oklahoma City, Oklahoma, United States.

B012 **Application of shallow whole genome sequencing to identify therapeutic opportunities in p53abn endometrial cancers.** Amy Jamieson. University of British Columbia, Vancouver, British Columbia, Canada.
B013 Folate receptor alpha (FRA) expression and correlation with other molecular alterations in high grade serous endometrial cancer (EC). Rebecca L. Porter. Dana-Farber Cancer Institute, Boston, Massachusetts, United States.


B015 A Novel Cluster 3 Endometrial Cancer PDX Model to Test Hormone Therapy Regimens. Kimberly K. Leslie. The University of New Mexico, Albuquerque, NM, United States.

B016 Novel Curcumin Analogues as Therapies for Endometrial Cancer with TP53 Mutations. Kimberly K. Leslie. The University of New Mexico, Albuquerque, NM, United States.


B018 MYC is sufficient to generate mid-life high-grade serous ovarian and serous endometrial carcinomas in a BRCA wild type p53-R270H mouse model. Alexandra Blackman. Medical University of South Carolina, Charleston, South Carolina, United States.

B019 Assessing Circulating Tumor DNA As A Prognostic Biomarker In Endometrial Cancer (The CODEC Study). Rachel Delahunty. Epworth Healthcare, Peter MacCallum Cancer, The Royal Women's Hospital, Melbourne, Australia.


B021 Early onset uterine corpus cancer incidence rates and 5-year relative survival by histologic subtype and race/ethnicity among women aged 20-49 years. Akemi T. Wijayabahu. Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland, United States.

B022 Conversion from Minimally Invasive surgical approaches to open surgery among endometrial cancer patients in a national cancer patients' registry. Ilana Chefetz. Mercer University, Macon, Georgia, United States.

Immune Landscape

B024 Immune exhaustion and reversal of progestin-related immune modulation in adaptive resistance to levonorgestrel intrauterine device for treatment of atypical hyperplasia and early endometrial cancer. Mikayla B. Bowen. MD Anderson Cancer Center, Houston, Texas, United States.
B025 IL6 signaling in pre-malignant obese endometrium and endometrial cancer. Qian Zhang. UT MD Anderson Cancer Center, Houston, Texas, United States.

B026 Substratification of mismatch repair deficient (MMRd) endometrial cancers can provide prognostic and predictive refinement. Amy Jamieson. University of British Columbia, Vancouver, British Columbia, United States.


B029 ARID1A/B mutations retarget mSWI/SNF chromatin remodeler activity and define a spectrum of dedifferentiation in endometrial carcinoma. Jessica D. St. Laurent. Brigham and Women's Hospital, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States.

B030 DNA methylation profiling identifies subset of low-grade endometrial neoplasms with poor response to progestin therapy. Lawrence H. Lin. Brigham and Women's Hospital - Harvard Medical School, Boston, Massachusetts, United States.

B031 High risk no specific molecular profile’ (HR-NSMP) endometrial cancer can be stratified into three subgroups based on tumor grade and estrogen receptor status with differing clinicopathologic characteristics and outcomes. Andrea Neilson. Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.

B032 Use of patient-derived organoids to model tumor evolution in response to chemotherapy. Kristina Thiel. University of Iowa, Omaha, Iowa, United States.

B033 Functional characterization of ALK5 (TGFBR1) mutations in endometrial cancer. Eun- Jeong Yu. NHGRI/NIH, Bethesda, Maryland, United States.
